Athanassios (Ethan) Argiris, MD

Argiris A, Stenson KM, Brockstein BE, et al. Neck dissection in the combined modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck, in press, 2003.

Haraf DJ, Rosen FR, Stenson K, Argiris A, Mittal BB, Witt ME, Brockstein BE, List MA, Portugal L, Pelzer H, Weichselbaum RR, Vokes EE. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 9(16 Pt 1):5936-5943, 2003.

Argiris A, Mellott A, Spies S. PET scan assessment of chemotherapy response in metastatic paraganglioma. Am J Clin Oncol 26(6):563-566, 2003.

Mittal BB, Pauloski BR, Haraf DJ, Pelzer HJ, Argiris A, Vokes EE, Rademaker A, Logemann JA. Swallowing dysfunction—preventive and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review. Int J Radiat Oncol Biol Phys 57(5):1219-1230, 2003.

Argiris A, Masters G. Carboplatin and gemcitabine for advanced NSCLC: an emerging standard doublet. Cancer Conf Highlights 7(10):5-8, 2003.

Argiris A, Haraf DJ, Kies MS, Vokes EE. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist 8(4):350-360, 2003.

Argiris A, Smith SM, Stenson K, Mittal BB, Pelzer HJ, Kies MS, Haraf DJ, Vokes EE. Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. Ann Oncol 14(8):1306-1311, 2003.

Argiris A, Eng C. Epidemiology, staging, and screening of head and neck cancer. Cancer Treat Res 114:15-60, 2003.

Argiris A, Dutra J, Tseke P, Haines K. Esthesioneuroblastoma: the Northwestern University experience. Laryngoscope 113(1):155-160, 2003.

Charles L. Bennett

Street VA, Bennett CL, Bird TD, Chance PF. New gene for CMT. J Peripher Nerv Syst 8(4):206, 2003.

Doherty MJ, Glass IA, Bennett CL, Cotter PD, Watson NF, Mitchell AL, Bird TD, Farrell DF. An Xp; Yq translocation causing a novel contiguous gene syndrome in brothers with generalized epilepsy, ichthyosis, and attention deficits. Epilepsia 44(12):1529-1535, 2003.

Bennett CL, Colledge L, Richards HE, Reay PA, Blackburn CC, Aebischer T. Uncompromised generation of a specific H-2DM-dependent peptide-MHC class II complex for exogenous antigen in Leishmania mexicana-infected dendritic cells. Eur J Immunol 33(12):3504-3513, 2003.

Parada JP, Deloria-Knoll M, Chmiel JS, Arozullah AM, Phan L, Ali SN, Goetz MB, Weinstein RA, Campo R, Jacobson J, Dehovitz J, Berland D, Bennett CL. Relationship between health insurance and medical care for patients hospitalized with human immunodeficiency virus-related Pneumocystis carinii pneumonia, 1995-1997: Medicaid, bronchoscopy, and survival. Clin Infect Dis 37(11):1549-1555, 2003.

Talamonti MS, Kim SP, Yao KA, Wayne JD, Feinglass J, Bennett CL, Rao S. Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery 134(4):720-729, 2003.

Bennett CL. Cost analyses of granulocyte colony stimulatin factor: a focus on older patients with cancer. Crit Rev Oncol Hematol 48 (Suppl):S71-S74, 2003.

Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, Kuzel TC, Tallman MS, Raisch DW, Auerbach AR, Schumock GT, Kwaan HC, Bennett CL. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 21(20):3859-3866, 2003.

Zhao JT, Bennett CL, Stewart GJ, Frommer M, Raphael KA. The scarlet eye colour gene of the tephritid fruit fly: Bactrocera tryoni and the nature of two eye colour mutations. Insect Mol Biol 12(3):263-29, 2003.

Bennett CL, Schumock GT. Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia: can they improve clinical decision making? Drugs Aging 20(7):479-483, 2003.

Arozullah AM, Parada J, Bennett CL, Deloria-Knoll M, Chmiel JS, Phan L, Yarnold PR. A rapid staging system for predicting mortality from HIV-associated community-acquired pneumonia. Chest 123(4):1151-1160, 2003.

Pfefer TJ, Matchette LS, Bennett CL, Gall JA, Wilke JN, Durkin AJ, Ediger MN. Reflectance-based determination of optical properties in highly attenuating tissue. J Biomed Opt 8(2):206-215, 2003.

Bennett CL, Somerfield MR, Pfister DG, Tomori C, Yakren S, Bach PB [American Society of Clinical Oncology]. Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. J Clin Oncol 21(5):937-941, 2003.

Calhoun EA, Bennett CL. Evaluating the total costs of cancer. The Northwestern University Costs of Cancer Program. Oncology 17(1):109-114, 2003.

Siston AK, Knight SJ, Slimack NP, Chmiel JS, Nadler RB, Lyons TM, Kuzel TM, Moran EM, Sharifi R, Bennett CL [Veterans Affairs Cancer of the Prostate Outcomes Study]. Quality of life after a diagnosis of prostate cancer among men of lower socioeconomic status: results from the Veterans Affairs Cancer of the Prostate Outcomes Study. Urology 61(1):172-178, 2003.

MacDonald LA, Meyers S, Bennett CL, Fintel D, Grosshans N, Syegco R, Davidson CJ. Post-cardiac catheterization access site complications and low-molecular-weight heparin following cardiac catheterization. J Invasive Cardiol 15(2):60-62, 2003.

Street VA, Bennett CL, Goldy JD, Shirk AJ, Kleopa KA, Tempel BL, Lipe HP, Scherer SS, Bird TD, Chance PF. Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology 60(1):22-26, 2003.

Al B. Benson III

Hecht JR, Blanke CD, Benson AB III, Lenz HJ. Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia. Oncology 17(9 Suppl 8):13-15, 2003.

Meyerhardt JA, Catalano PJ, Schrag D, Ayanian JZ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III, Fuchs CS. Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med 139(8):649-657, 2003.

Benson AB III. Phase III trial of 5-fluorouracil-based chemotherapy regimens plus radiation therapy in postoperative adjuvant therapy for rectal cancer: Intergroup 0144. Cancer Conf Highlights 7(13):8-10, 2003.

Benson AB III [Guest Editor]. New perspectives in the management of upper gastrointestinal malignancies [Introduction]. Semin Oncol 30(4, Suppl 11):1-2, 2003.

Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB III, Macdonald JS, Fuchs CS. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 98(3):484-495, 2003.

Weinfurt KP, Castel LD, Li Y, Sulmasy DP, Balshem AM, Benson AB III, Burnett CB, Gaskin DJ, Marshall JL, Slater EF, Schulman KA, Meropol NJ. The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer 98(1):166-175, 2003.

Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson AB III, Castel L, Corbett S, Diefenbach M, Gaskin D, Li Y, Manne S, Marshall J, Rowland JH, Slater E, Sulmasy DP, Van Echo D, Washington S, Schulman KA. Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol 21(13):2589-2596, 2003.

Benson AB III, Goldberg RM. Optimal use of the combination of irinotecan and 5-fluorouracil. Semin Oncol 30(3, Suppl 6):68-77, 2003.

Johnston PG, Benson AB III, Catalano P, Rao MS, O’Dwyer PJ, Allegra CJ. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 21(5):815-819, 2003.

Benson A III [Guest Editor]. Chemotherapy of solid malignancies: focus on phase I/II clinical trials of ZD9331, a new direct-acting antifolate. Anti Cancer Drugs 14(Suppl 1), 2003.

Benson A III, Poplin E, Vergote I. ZD9331 in combination with topotecan: phase I and II experience. Anti Cancer Drugs 14(Suppl 1):S21-S27, 2003.

Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III, Fuchs CS. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 21(3):433-440, 2003.

Mulcahy MF, Benson AB III. New agents for colorectal cancer. J Natl Comprehensive Cancer Netw 1(1):125-136, 2003.

Raymond C. Bergan

Takimoto CH, Glover K, Huang X, Hayes SA, Gallot L, Quinn M, Jovanovic BD, Shapiro A, Hernandez L, Goetz A, Llorens V, Lieberman R, Crowell JA, Poisson BA, Bergan RC. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 12(11 Pt 1):1213-1221, 2003.

Hayes SA, Huang X, Kambhampati S, Platanias LC, Bergan RC. p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene 22(31):4841-4850, 2003.

Jackie Cameron

Javad Mortazavi SM, Cameron JR, Niroomand-rad A. Adaptive response studies may help choose astronauts for long-term space travel. Adv Space Res 31(6):1543-1551, 2003.

Elizabeth A. Eklund

Lu Y, Goldenberg I, Bei L, Andrejic J, Eklund EA. HoxA 10 represses gene transcription in undifferentiated myeloid cells by interaction with histone deacetylase 2. J Biol Chem 2003. [Epub ahead of print]

Andrew M. Evens

Shi B, Hsu HL, Evens AM, Gordon LI, Gartenhaus RB. Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies. Blood 102(1):297-302, 2003.

Evens AM, Gartenhaus RB. Molecular etiology of mature T-cell non-Hodgkin’s lymphomas. Front Biosci 8:d156-175, 2003.

Ronald B. Gartenhaus

Nasedkina TV, Zharinov VS, Isaeva EA, Yurasov R, Turigin AY, Karachunskii AI, Gartenhaus RB, Mirzabekov AD. Clinical screening of gene rearrangements in childhood leukemia by using a multiplex polymerase chain reaction-microarray approach. Clin Cancer Res 9(15):5620-5629, 2003.

Frankel AE, Fleming DR, Hall PD, Powell BL, Black JH, Leftwich C, Gartenhaus R. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine refractory chronic lymphocytic leukemia. Clin Cancer Res 9(10 Pt 1):3555-3561, 2003.

Shi B, Levenson V, Gartenhaus RB. Identification and characterization of a novel enhancer for the human MCT-1 oncogene promoter. J Cell Biochem 90(1):68-79, 2003.

Frankel AE, Fleming DR, Powell BL, Gartenhaus R. DAB(389)IL2 (ONTAK(R)) fusion protein therapy of chronic lymphocytic leukaemia. Expert Opin Biol Ther 3(1):179-186, 2003.

Shi B, Hsu HL, Evens AM, Gordon LI, Gartenhaus RB. Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies. Blood 102(1):297-302, 2003.

Evens AM, Gartenhaus RB. Molecular etiology of mature T-cell non-Hodgkin’s lymphomas. Front Biosci 8:d156-175, 2003.

Leo I. Gordon

Gordon LI. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Oncol 30(6 Suppl 17):23-28, 2003.

Ali MY, Oyama Y, Monreal J, Winter JN, Tallman TS, Williams SF, Singhal S, Gordon LI, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 31(10):861-864, 2003.

Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma. J Clin Oncol 21(7):1263-1270, 2003.

Shi B, Hsu HL, Evens AM, Gordon LI, Gartenhaus RB. Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies. Blood 102(1):297-302, 2003.

William J. Gradishar

Gradishar WJ. Tamoxifen – what next? The Oncologist, in press, 2003.

Gradishar WJ, O’Regan RM. Progress in systemic adjuvant therapy of early-stage breast cancer. Int J Clin Oncol 8(4):239-247, 2003.

Bartelink H, Benz C, Cleveland D, Dorn R, Gralow J, Gradishar WJ, Grant K, Heimann R, Hellman S, Hudis C, Kerbel R, Lippman M, Lung J, Posner MC, Steeg P, Vestal R, Weichselbaum RR, Zetter B. Expedition Inspiration Fund for Breast Cancer Research Meeting 2003. Breast Cancer Res Treat 80(2):139-144, 2003.

Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349(1):17-26, 2003.

Kaklamani VG, Gradishar WJ. Epirubicin vs. doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clinical Breast Cancer 4(Supp 1):S26-S33, 2003.

Allred DC, Baum M, Buzdar AU, Carlson RW, Dowsett M, Elledge RM, Gradishar WJ, Grana G, Howell A, Mamounas EP. A roundtable discussion of aromatase inhibitors as therapy for breast cancer. Breast J 9(3):213-222, 2003.

Kaklamani VG, Gradishar WJ. Role of capecitabine (XelodaÒ) in breast cancer. Expert Rev Anticancer Ther 3(2):137-144, 2003.

Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose dense vs. conventionally scheduled and sequential vs. concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup C9741 – CALGB 9741. J Clin Oncol 21(11):1431-1439, 2003.

Kaklamani VG, Gradishar WJ. Advances in adjuvant chemotherapy of breast cancer: the role of taxanes. J Natl Comprehensive Cancer Network 1(Suppl 1):S107-S118, 2003.

Gradishar WJ. Adjuvant systemic therapy of early stage breast cancer. Curr Treat Options Oncol 4(2):141-150, 2003.

Gradishar WJ. The role of aromatase inhibitors as first- and second-line therapy for hormone-sensitive metastatic breast cancer. Curr Oncol 10(Suppl 1):S14-S19, 2003.

David Green

Green D, Hartwig D, Chen D, Soltysik RC, Yarnold PR. Spinal cord injury risk assessment for thromboembolism (SPIRATE Study). Am J Phys Med Rehabil 82(12):950-956, 2003.

McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, Taylor L, Chan C, Sharma L, Schneider JR, Ridker PM, Green D, Quann M. Statin use and leg functioning in patients with and without lower extremity peripheral arterial disease. Circulation 107:757-761, 2003.

Merli G, Geerts W, Ginzburg E, Green D, Lambert R, Leduc B, McKean J, Wing P [Spinal Cord Injury Thromboprophylaxis Investigators Steering Committee]. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. J Trauma 54:1116-1126, 2003.

Merli G, Geerts W, Ginzburg E, Green D, Lambert R, Leduc B, McKean J, Wing P [Spinal Cord Injury Thromboprophylaxis Investigators]. Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin. J Trauma 54:1111-1115, 2003.

McDermott MM, Greenland P, Green D, Guralnik JM, Criqui MH, Liu K, Chan C, Pearce WH, Taylor L, Ridker PM, Schneider JR, Martin G, Rifai N, Quann M, Fornage M. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation 2003; 107:3191-3198.

McDermott MM, Green D, Greenland P, Liu K, Criqui MH, Chan C, Pearce WH, Ridker PM, Guralnik JM, Taylor L, Rifai N, Schneider JR. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 92:194-199, 2003.

Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349:1133-1138, 2003.

Virginia G. Kaklamani

Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A, Pasche B. TGFBR1*6A and cancer: a meta-analysis of seven case-control studies. J Clin Oncol 21(17):3236-3243, 2003.

Kaklamani VG, Tzonou A, Markomichelakis N, Papazoglou S, Kaklamanis PG. The effect of smoking on the clinic features of Adamantiades-Behcet’s disease. Adv Exp Med Biol 528:323-327, 2003.

Kaklamani VG, Gradishar WJ. Epirubicin vs. doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clinical Breast Cancer 4(Supp 1):S26-S33, 2003.

Kaklamani VG, Gradishar WJ. Role of capecitabine (XelodaÒ) in breast cancer. Expert Rev Anticancer Ther 3(2):137-144, 2003.

Kaklamani VG, Gradishar WJ. Advances in adjuvant chemotherapy of breast cancer: the role of taxanes. J Natl Comprehensive Cancer Network 1(Suppl 1):S107-S118, 2003.

Bian Y, Kaklamani V, Reich J, Pasche B. TGF-beta signaling alterations in cancer. Cancer Treat Res 115:73-94, 2003.

Timothy M. Kuzel

Oyama Y, Guitart J, Kuzel TM, Burt RK, Rosen ST. High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 17(6):1475-83, 2003.

Kuzel TM, Junghans R, Foss FM. Novel agents for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 17(6):1459-1466, 2003.

Rook AH, Kuzel TM, Olsen EA. Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am 17(6):1435-1448, 2003.

Kuzel TM. Systemic chemotherapy for the treatment of mycosis fungoides and Sezary syndrome. Dermatol Ther 16(4):355-361, 2003.

Querfeld C, Rosen ST, Kuzel TM, Guitart J. Cutaneous T-cell lymphomas: a review with emphasis on new treatment approaches. Semin Cutan Med Surg 22(3):150-161, 2003.

Burt RK, Drobyski WR, Seregina T, Traynor A, Oyama Y, Keever-Taylor C, Stefka J, Kuzel TM, Brush M, Rodriquez J, Burns W, Tennant L, Link C. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp Hermatol 31(10):903-910, 2003.

Querfeld C, Guitart J, Kuzel TM, Rosen ST. Primary cutaneous lymphomas: a review with current treatment options. Blood Rev 17(3):131-142, 2003.

Wu JJ, Guitart J, Tucker RM, Kuzel TM, Rosen ST. Secondary cutaneous anaplastic large cell lymphoma treated with liposomal doxorubicin (Doxil) leading to complete remission. Int J Dermatol 42(6):464-465, 2003.

Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, Kuzel TC, Tallman MS, Raisch DW, Auerbach AR, Schumock GT, Kwaan HC, Bennett CL. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 21(20):3859-3866, 2003.

Siston AK, Knight SJ, Slimack NP, Chmiel JS, Nadler RB, Lyons TM, Kuzel TM, Moran EM, Sharifi R, Bennett CL [Veterans Affairs Cancer of the Prostate Outcomes Study]. Quality of life after a diagnosis of prostate cancer among men of lower socioeconomic status: results from the Veterans Affairs Cancer of the Prostate Outcomes Study. Urology 61(1):172-178, 2003.

Hau C. Kwaan

Zarkovic M, Kwaan HC. Correction of hyperviscosity by apheresis. Semin Thromb Hemost 29(5):535-542, 2003.

Kwaan HC, Sakurai S, Wang J. Rheological abnormalities and thromboembolic complications in heart disease: spontaneous echo contrast and red cell aggregation. Semin Thromb Hemost 29(5):529-534, 2003.

Baronzio G, Freitas I, Kwaan HC. Tumor microenvironment and hemorheological abnormalities. Semin Thromb Hemost 29(5):489-497, 2003.

Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost 29(5);451-458, 2003.

Kwaan HC. The hyperviscosity syndromes. Semin Thromb Hemost 29(5):433-434, 2003.

Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, Kuzel TC, Tallman MS, Raisch DW, Auerbach AR, Schumock GT, Kwaan HC, Bennett CL. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 21(20):3859-3866, 2003.

Kwaan HC, Parmar S, Wang J. Pathogenesis of increased risk of thrombosis in cancer. Sem Thromb Hemost 29:283-290, 2003.

Zakarija A, Kwaan HC. Bleeding and thrombosis in the cancer patient. Expert Rev Cardiovasc Ther 1:271-281, 2003.

Kwaan HC. Book review: Thrombosis and Hemorrhage, Loscalzo J, Schafer AI (eds). JAMA 289:3014-3015, 2003.

Nabhan C, Kwaan HC. Current concepts in the diagnosis and management of thrombotic thrombocytopenia purpura. Hematol Oncol Clin N Am 17:177-199, 2003.

Kwaan HC, Nabhan C. Hereditary and acquired defects in the fibrinolytic system associated with thrombosis. Hematol Oncol Clin N Am 17:103-114, 2003.

Jayesh Mehta

Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B [Scientific Advisors of the International Myeloma Foundation]. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4(6):379-388, 2003.

Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost 29(5):467-471, 2003.

Kulkarni S, Powles R, Sirohi B, Treleaven J, Horton C, Atra A, Rudin C, Goyal S, Sankpal S, Meller S, Pinkerton CR, Mehta J, Singhal S. Thalidomide after allogeneic hematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 32(2):165-170, 2003.

Mehta J, Powles R, Sirohi B, Treleaven J, Swansbury GJ, Kulkarni S, Saso R, Singhal S. Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pre-transplant therapy limited to patients with good karyotypes? Bone Marrow Transplant 32(2):157-164, 2003.

Singhal S, Henslee-Downey PJ, Powles R, Chiang KY, Godder K, Treleaven J, Kulkarni S, van Rhee F, Sirohi B, Pinkerton CR, Meller S, Jovanovic B, Mehta J. Haploidentical vs autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission. Bone Marrow Transplant 31(10):889-895, 2003.

Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF, Singhal S, Gordon LI, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 31(10):861-864, 2003.

Singhal S, Mehta J. Treatment of relapsed and refractory multiple myeloma. Curr Treatment Options Oncol 4(3):229-237, 2003.

Pichardo D, Singhal S, Mehta J, Rosen S. Recent developments and future directions in the treatment of multiple myeloma. Cancer Biother Radiopharm 18:497-511, 2003.

Singhal S, Mehta J. Novel therapies in myeloma. Int J Hematol 77(3):226-231, 2003.

Desikan R, Barlogie B, Sethi R, Toor A, Spoon D, Angtuaco E, Vanhemert R, Vijayagopal A, Singhal S, Mehta J, Jagannath S, Munshi N, Zangari M, Fassas A, Tricot G, Anaissie E. Infection - an underappreciated cause of bone pain in multiple myeloma. Br J Haematol 120(6):1047-1050, 2003.

Singhal S, Mehta J. Easy to see but hard to find. N Engl J Med 348(19):1931-1932, 2003.

Mary F. Mulcahy

Mulcahy MF, Benson AB III. New agents for colorectal cancer. J Natl Comprehensive Cancer Netw 1(1):125-136, 2003.

Judith A. Paice

Paice J. Sexuality and pain control. AJN 103(1):87-89, 2003.

Paice J. Mechanisms and management of neuropathic pain in cancer. J Supp Oncol 1(2):107-120, 2003.

Cleeland CS, Reyes-Gibby CC, Schall M, Paice J, Rosenberg J, Tollett JH, Kerns RD I. Rapid improvement in pain management: the Veterans Health Administration and the Institute for Healthcare Improvement Collaborative. Clin J Pain 19:298-305, 2003.

Boris Pasche

Bian Y, Kaklamani V, Reich J, Pasche B. TGF-beta signaling alterations in cancer. Cancer Treat Res 115:73-94, 2003.

Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A, Pasche B. TGFBR1*6A and cancer: a meta-analysis of seven case-control studies. J Clin Oncol 21(17):3236-3243, 2003.

Jyoti D. Patel

Patel JD, Ebert M, Stokes K, Ward R, Anderson JM. Inhibition of bacterial and leukocyte adhesion under shear stress conditions by material surface chemistry. J Biomater Sci Polym Ed 14(3):279-295, 2003.

Patel JD, Krug LM, Azzoli CG, Gomez J, Kris MG, Miller VA. Targeting lethal minimal residual disease in small cell lung cancer. Semin Oncol 30(1):79-85, 2003.

Leonidas C. Platanias

Parmar S, Platanias LC. Inferferons: mechanisms of action and clinical applications. Curr Opin Oncol 15(6):431-439, 2003.

Deonarain R, Verma A, Porter AC, Gewert DR, Platanias LC, Fish EN. Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc Natl Acad Sci USA 100(23):13453-13458, 2003.

Uddin S, Lekmine F, Sassano A, Rui H, Fish EN, Platanias LC. Role of Stat5 in type I interferon-signaling and transcriptional regulation. Biochem Biophys Res Commun 308(2):325-330, 2003.

Hayes SA, Huang X, Kambhampati S, Platanias LC, Bergan RC. p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene 22(31):4841-4850, 2003.

Verma A, Kambhampati S, Parmar C, Platanias LC. Jak family of kinases in cancer. Cancer Metastasis Rev 22(4):423-434, 2003.

Deb DK, Sassano A, Lekmine F, Majchrzak B, Verma A, Kambhampati S, Uddin S, Rahman A, Fish EN, Platanias LC. Activation of protein kinase Cdelta by IFN-gamma. J Immunol 171(1):267-273, 2003.

Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK, Parmar S, Giafis N, Kalvakolanu DV, Rahman A, Uddin S, Minucci S, Tallman MS, Fish EN, Platanias LC. Activation of protein kinase C-delta (PKC-delta) by all-trans-retinoic acid. J Biol Chem 2003 [electronic publication].

Lekmine F, Uddin S, Sassano A, Parmar S, Brachmann SM, Majchrzak B, Sonenberg N, Hay N, Fish EN, Platanias LC. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem 278(30):27772-27780, 2003.

Platanias LC. The p38 mitogen-activated protein kinase pathway and its role in interferon signaliing. Pharmacol Ther 98(2):129-142, 2003.

Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 101(12):4667-4679, 2003.

Steven T. Rosen

Oyama Y, Guitart J, Kuzel TM, Burt RK, Rosen ST. High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 17(6):1475-83, 2003.

Querfeld C, Rosen ST, Kuzel TM, Guitart J. Cutaneous T-cell lymphomas: a review with emphasis on new treatment approaches. Semin Cutan Med Surg 22(3):150-161, 2003.

Querfeld C, Guitart J, Kuzel TM, Rosen ST. Primary cutaneous lymphomas: a review with current treatment options. Blood Rev 17(3):131-142, 2003.

Wu JJ, Guitart J, Tucker RM, Kuzel TM, Rosen ST. Secondary cutaneous anaplastic large cell lymphoma treated with liposomal doxorubicin (Doxil) leading to complete remission. Int J Dermatol 42(6):464-465, 2003.

Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC, Rosen ST. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and –resistant MM cells. Exp Hematol 31(4):271-282, 2003.

Pichardo D, Singhal S, Mehta J, Rosen S. Recent developments and future directions in the treatment of multiple myeloma. Cancer Biother Radiopharm 18(4):497-511, 2003.

Nabhan C, Dyer MJ, Rosen ST. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia. Oncology 17(2):253-262, 2003.

Seema Singhal

Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B [Scientific Advisors of the International Myeloma Foundation]. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4(6):379-388, 2003.

Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost 29(5):467-471, 2003.

Kulkarni S, Powles R, Sirohi B, Treleaven J, Horton C, Atra A, Rudin C, Goyal S, Sankpal S, Meller S, Pinkerton CR, Mehta J, Singhal S. Thalidomide after allogeneic hematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 32(2):165-170, 2003.

Mehta J, Powles R, Sirohi B, Treleaven J, Swansbury GJ, Kulkarni S, Saso R, Singhal S. Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pre-transplant therapy limited to patients with good karyotypes? Bone Marrow Transplant 32(2):157-164, 2003.

Singhal S, Henslee-Downey PJ, Powles R, Chiang KY, Godder K, Treleaven J, Kulkarni S, van Rhee F, Sirohi B, Pinkerton CR, Meller S, Jovanovic B, Mehta J. Haploidentical vs autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission. Bone Marrow Transplant 31(10):889-895, 2003.

Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF, Singhal S, Gordon LI, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 31(10):861-864, 2003.

Singhal S, Mehta J. Treatment of relapsed and refractory multiple myeloma. Curr Treatment Options Oncol 4(3):229-237, 2003.

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609-2617, 2003.

Pichardo D, Singhal S, Mehta J, Rosen S. Recent developments and future directions in the treatment of multiple myeloma. Cancer Biother Radiopharm 18:497-511, 2003.

Singhal S, Mehta J. Novel therapies in myeloma. Int J Hematol 77(3):226-231, 2003.

Desikan R, Barlogie B, Sethi R, Toor A, Spoon D, Angtuaco E, Vanhemert R, Vijayagopal A, Singhal S, Mehta J, Jagannath S, Munshi N, Zangari M, Fassas A, Tricot G, Anaissie E. Infection - an underappreciated cause of bone pain in multiple myeloma. Br J Haematol 120(6):1047-1050, 2003.

Singhal S, Mehta J. Easy to see but hard to find. N Engl J Med 348(19):1931-1932; 2003.

Singhal S. Treatment of multiple myeloma. BMJ 327(7415):575-576, 2003.

Gerald A. Soff

Bai X, Cerimele F. Ushio-Fukai M, Waqas M, Campbell P, Govindarajan B, Der C, Battle T, Frank DA, Ye K, Cohen P, Murad E, Dubiel W, Soff GA, Arbiser JL. Honokiol, a small molecular weight natural product, inhibits phosphoinositol 3-kinase/ras signaling in vitro and tumor growth in vivo. J Biol Chem 278(37)35501-35507, 2003.

Soff GA. Angiostatin and hematocellular carcinoma. Hepatology 37(3):696-704, 2003.

Hanford HA, Wong CA, Kassan H, Cundiff DL, Chandel N, Underwood S, Mitchell CA, Soff GA. Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells. Cancer Res 63(14):4275-4280, 2003.

Martin S. Tallman

Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, LoCocco F [International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials of Acute Myeloid Leukemia]. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatmetn Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21(24)4642-4649, 2003.

Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology:82-101, 2003.

Tallman MS. Preface. Best Pract Res Clin Haematol 16(3):347, 2003.

Parmar S, Tallman MS. Acute promyelocytic leukaemia: a review. Expert Opin Pharmacother 4(8):1379-1392, 2003.

Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349(1):17-26, 2003.

Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, Kuzel TC, Tallman MS, Raisch DW, Auerbach AR, Schumock GT, Kwaan HC, Bennett CL. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 21(20):3859-3866, 2003.

Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, Hrisinko MA, Peterson LC. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status. Am J Clin Pathol 119(6):833-841, 2003.

Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK, Parmar S, Giafis N, Kalvakolanu DV, Rahman A, Uddin S, Minucci S, Tallman MS, Fish EN, Platanias LC. Activation of protein kinase C-delta (PKC-delta) by all-trans-retinoic acid. J Biol Chem 278(35):32544-32551, 2003 [electronic publication].

Ali MY, Oyama Y, Monreal J, Winter JN, Tallman TS, Williams SF, Singhal S, Gordon LI, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 31(10):861-864, 2003.

Zakarija A, Peterson LC, Tallman MS. Splenectomy and treatments of historical interest. Best Pract Res Clin Haematol 16(1):57-68, 2003.

Frater JL, Yaseen NR, Peterson LC, Tallman MS, Goolsby CL. Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage. Arch Pathol Lab Med 127(3):356-359, 2003.

Benzon HT, Iqbal M, Tallman MS, Boehlke L, Russell EJ. Superior sagittal sinus thrombosis in a patient with postdural puncture headache. Reg Anesth Pain Med 28(1):64-67, 2003.

Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S, Bloomfield CD, Appelbaum FR, Tallman MS, Slack JL, Willman CL. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 101(7):2521-2528, 2003.

Tallman MS. Bleeding in acute leukemia. Pathophysiol Haemost Thromb 33(1):48-9, 2003.

Cherry AM, Brockman SR, Paternoster SF, Hicks GA, Neuberg D, Higgins RR, Bennett JM, Greenberg PL, Miller K, Tallman MS, Rowe J, Dewald GW. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk Res 27(12):1085-1090, 2003.

Tomblyn MR, Tallman MS. New developments in antibody therapy for acute myeloid leukemia. Semin Oncol 30(4):502-508, 2003.

Tallman MS, Rowe JM. Long-term follow-up and potential for cure in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16(3):535-543, 2003.

Larson RS, Tallman MS. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol 16(3):453-461, 2003.

Avvisati G, Tallman MS. All-trans retinoic acid in acute promyelocytic leukaemia. Best Practice Res Clin Haematol 16(3):419-432, 2003.

Paietta E, Neuberg D, Bennett JM, Dewald G, Rowe JM, Cassileth PA, Cripe L, Tallman MS, Wiernik PH; Eastern Cooperative Oncology Group. Low expression of the myeloid differentiation antigen CD64s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials. Leukemia 17(8):1544-1550, 2003.

Jamie H. Von Roenn

Ambinder RF, Lee S, Curran WJ, Sparano JA, Krigel RL, McArthur J, Schultz C, Freter CE, Kaplan L, Von Roenn JH. Phase II intergroup trial of sequential chemotherapy and radiotherapy for AIDS-related primary central nervous system lymphoma. Cancer Ther 1:215-221, 2003 [electronically publication].

Chang C-H, Cella D, Clarke S, Heinemann AW, Von Roenn JH, Harvey R. Should symptoms be scaled for intensity, frequency, or both? Palliat Supp Care 1:51-60, 2003.

Von Roenn JH. Clinical presentations and standard therapy of AIDS-associated Kaposi’s sarcoma. Hematol Oncol Clin N Am 17:747-762, 2003.

Sigmund A. Weitzman

Panduri V, Weitzman SA, Chandel N, Kamp DW. The mitochondria-regulated death pathway mediates asbestos-induced alveolar epithelial cell apoptosis. Am J Respir Cell Mol Biol 28(2):241-248, 2003.

Jane N. Winter

Tomblyn M, Winter JN. Autologous hematopoietic stem cell transplant in first remission in non-Hodgkin’s lymphoma. Expert Rev Anticancer Ther 3(3):281-294, 2003.

Ali MY, Oyama Y, Monreal J, Winter JN, Tallman TS, Williams SF, Singhal S, Gordon LI, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 31(10):861-864, 2003.

Winter JN. Targeting CD20. Blood 101(11):4227, 2003.